Molecular identification of mutations conferring resistance to rifampin, isoniazid and pyrazinamide among <i>Mycobacterium tuberculosis</i> isolates from Iran
Haratiasl AA, Hamzelou G, Amini S, Kardan-Yamchi J, Haeili M, Heidari F, Feizabadi MM
Journal of chemotherapy (Florence, Italy) · 2020-02
Abstract
Here, we aimed to determine the susceptibility of 70 Mycobacterium tuberculosis isolates obtained from different regions of the country to 8 anti-tuberculosis (anti-TB) drugs and possible underlying mechanisms causing resistance to rifampin, isoniazid, and pyrazinamide. The susceptibility of 70 isolates of M. tuberculosis to anti-TB drugs was tested using proportion method. Strains showing resistance to the first line anti-TB drugs were subjected to PCR amplification and sequencing of the rpoB, katG, ahpC, pncA genes, inhA promoter and oxyR-ahpC intergenic regions to detect resistance conferring mutations. Overall, 77.1% and 77.1% of isolates were resistant to at least one of the tested first- and second-line drugs, respectively. Within the rpoB gene the highest rate of mutation was found in codons 531(450) (56.3%), and 533(452) (12.5%). Also, codons 315 (42.4%) of katG, positions -48, -72 and -77 of oxyR-ahpC (total= 3, 9.1%) and -15 of inhA promoter region (33.3%) were the most altered positions in isoniazid resistant isolates. Only a single mutation was detected for pncA among resistant isolates. High prevalence of resistance to essential anti-TB drugs among M. tuberculosis strains isolated from retreated tuberculosis cases is alarming issue necessitating immediate action to prevent the spread of drug resistant isolates in the country.
MeSH terms
- Humans
- Mycobacterium tuberculosis
- Isoniazid
- Pyrazinamide
- Rifampin
- Bacterial Proteins
- DNA, Bacterial
- Antitubercular Agents
- Microbial Sensitivity Tests
- Iran
- Promoter Regions, Genetic